Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29430118 | 1.00 | MEN1 (0.53) | MEN1KMT2ARORCALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL17103200 | 0.99 | MEN1 (0.52) | MEN1KMT2ARORCALDH1A1PKM | |
| Sulfuric Acid SCHEMBL17103345 | 0.96 | KMT2A (0.52) | MEN1KMT2ARORCALDH1A1PKM | |
| Sulfuric Acid SCHEMBL17103341 | 0.96 | KMT2A (0.52) | MEN1KMT2ARORCALDH1A1PKM | |
| SCHEMBL17103196 | 0.89 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1PKMCRHBP | |
| SCHEMBL17103220 | 0.89 | KMT2A (0.54) | MEN1KMT2ARORCALDH1A1PKM | |
| SCHEMBL17122765 | 0.89 | MEN1 (0.54) | MEN1KMT2ARORCALDH1A1PKM | |
| SCHEMBL17103449 | 0.89 | ALDH1A1 (0.43) | MEN1KMT2ARORCALDH1A1PKM | |
| SCHEMBL17122561 | 0.89 | KMT2A (0.55) | MEN1KMT2AALDH1A1PKMCRHBP | |
| SCHEMBL17228270 | 0.89 | ALDH1A1 (0.48) | MEN1KMT2AALDH1A1PKMCRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109746-A1 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4720056-A1 | SOLID FORMS OF COMPOUNDS USEFUL IN THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719608-A1 | QUINAZOLINYL-INDAZOLE DERIVATIVES AS THERAPEUTIC COMPOUNDS FOR HIV | GILEAD SCIENCES, INC. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4698174-A1 | DOSING REGIMEN OF CAPSID INHIBITOR | GILEAD SCIENCES, INC. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12559546-B2 | Methods of identifying HIV patients sensitive to therapy with gp120 CD4 binding site-directed antibodies | GILEAD SCIENCES, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4244396-B9 | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH GP120 CD4 BINDING SITE-DIRECTED ANTIBODIES | GILEAD SCIENCES INC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007683-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING HIV INTEGRASE INHIBITORS | GILEAD SCIENCES INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4667477-A2 | PRODRUGS OF PHOSPHONAMIDE NUCLEOTIDE ANALOGUES AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-2924021-B1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | UNIV SICHUAN (CN) | 2019-08-28 | — | — | EP | disclosed |
| EP-2924021-B1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | UNIV SICHUAN (CN) | 2019-08-28 | — | — | EP | disclosed |
| US-9402819-B2 | Anti-HIV compound and preparation method and use thereof | SICHUAN UNIVERSITY (CN) | 2016-08-02 | — | — | US | disclosed |
| US-9402819-B2 | Anti-HIV compound and preparation method and use thereof | SICHUAN UNIVERSITY (CN) | 2016-08-02 | — | — | US | disclosed |
| US-9402819-B2 | Anti-HIV compound and preparation method and use thereof | SICHUAN UNIVERSITY (CN) | 2016-08-02 | — | — | US | disclosed |
| US-20150313853-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN UNIVERSITY (CN) | 2015-11-05 | — | — | US | disclosed |
| US-20150313853-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN UNIVERSITY (CN) | 2015-11-05 | — | — | US | disclosed |
| US-20150313853-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN UNIVERSITY (CN) | 2015-11-05 | — | — | US | disclosed |
| EP-2924021-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | Sichuan University (CN) | 2015-09-30 | — | — | EP | disclosed |
| EP-2924021-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | Sichuan University (CN) | 2015-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007683-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING HIV INTEGRASE INHIBITORS | DSTYK, INMT, JAK1 | MEN1 4344/4885KMT2A 195/4885RORC 2169/4885 |
| US-12559546-B2 | Methods of identifying HIV patients sensitive to therapy with gp120 CD4 binding site-directed antibodies | CD4, IGSF11, VSIG8 | MEN1 4371/4885KMT2A 77/4885RORC 1917/4885 |
| US-20260109746-A1 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | IL15, IL15RA, CD4 | MEN1 973/4885KMT2A 3253/4885RORC 2543/4885 |
| US-20150313853-A1 | ANTI-HIV COMPOUND AND PREPARATION METHOD AND USE THEREOF | FURIN, CD4, SI | MEN1 3628/4885KMT2A 3442/4885RORC 1024/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | MEN1 4805/4885KMT2A 4244/4885RORC 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.